196 related articles for article (PubMed ID: 38482976)
1. In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy.
Luo Z; Wan Z; Ren P; Zhang B; Huang Y; West RE; Huang H; Chen Y; Nolin TD; Xie W; Wang J; Li S; Sun J
Adv Sci (Weinh); 2024 May; 11(19):e2307940. PubMed ID: 38482976
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
[TBL] [Abstract][Full Text] [Related]
3. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Vendetti F; Vancriekinge W; Demeyer T; Du Z; Parsana P; Rodgers K; Yen RW; Zahnow CA; Taube JM; Brahmer JR; Tykodi SS; Easton K; Carvajal RD; Jones PA; Laird PW; Weisenberger DJ; Tsai S; Juergens RA; Topalian SL; Rudin CM; Brock MV; Pardoll D; Baylin SB
Oncotarget; 2013 Nov; 4(11):2067-79. PubMed ID: 24162015
[TBL] [Abstract][Full Text] [Related]
4. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
6. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
[TBL] [Abstract][Full Text] [Related]
7. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy.
Sun J; Chen Y; Xu J; Song X; Wan Z; Du Y; Ma W; Li X; Zhang L; Li S
Theranostics; 2020; 10(3):1136-1150. PubMed ID: 31938056
[TBL] [Abstract][Full Text] [Related]
8. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
11. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
[TBL] [Abstract][Full Text] [Related]
13. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
15. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
16. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
Bogatyrova O; Mattsson JSM; Ross EM; Sanderson MP; Backman M; Botling J; Brunnström H; Kurppa P; La Fleur L; Strell C; Wilm C; Zimmermann A; Esdar C; Micke P
Eur J Cancer; 2021 Jul; 151():136-149. PubMed ID: 33984662
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles.
Yu L; Xu M; Xu W; Xiao W; Jiang XH; Wang L; Gao H
Nano Lett; 2020 Dec; 20(12):8903-8911. PubMed ID: 33232167
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C; Sgarioto N; Yu Z; Sesma-Sanz L; Masson JY; Richard S; Raynal NJ
Clin Epigenetics; 2021 Mar; 13(1):54. PubMed ID: 33691794
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P
J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616
[TBL] [Abstract][Full Text] [Related]
20. Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects.
Qiu X; Liang Y; Sellers RS; Perez-Soler R; Zou Y
PLoS One; 2014; 9(10):e109874. PubMed ID: 25347303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]